Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
62 participants
INTERVENTIONAL
2014-05-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers
NCT02174835
Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers
NCT01787747
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
NCT03420222
A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir
NCT02262715
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
NCT04366115
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 - Period 1
Twice daily dosing of AVP-786 orally for 8 days
AVP-786
Group 1 - Period 2
Twice daily dosing of AVP-923 orally for 8 days
AVP-923
Group 2 - Period 1
Twice daily dosing of AVP-923 orally for 8 days
AVP-923
Group 2 - Period 2
Twice daily dosing of AVP-786 orally for 8 days
AVP-786
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AVP-786
AVP-923
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 - 60 years of age
* BMI 18 - 32 kg/m2
Exclusion Criteria
* History of substance abuse and/or alcohol abuse with the past 2 years
* Use of tobacco-containing or nicotine-containing products within 6 months
* Use of any prescription or the over-the-counter medications within 14 days
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Avanir Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nadine Knowles
Role: STUDY_DIRECTOR
Avanir Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Covance Dallas Clinical Research Unit
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-AVP-786-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.